Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 2
2004 3
2005 4
2006 4
2007 10
2008 13
2009 16
2010 22
2011 38
2012 40
2013 48
2014 56
2015 51
2016 35
2017 42
2018 36
2019 47
2020 43
2021 37
2022 20
2023 19
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

493 results

Results by year

Filters applied: . Clear all
Page 1
The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
Norata GD, Garlanda C, Catapano AL. Norata GD, et al. Trends Cardiovasc Med. 2010 Feb;20(2):35-40. doi: 10.1016/j.tcm.2010.03.005. Trends Cardiovasc Med. 2010. PMID: 20656213 Review.
PTX3 in humans, like CRP, is a marker of atherosclerosis and correlates with the risk of developing vascular events. ...Although these observations point to a cardiovascular protective effect of PTX3, they also suggest the possibility that the increased level …
PTX3 in humans, like CRP, is a marker of atherosclerosis and correlates with the risk of developing vascular events. ...Although thes …
The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study.
Yilmaz MI, Romano M, Basarali MK, Elzagallaai A, Karaman M, Demir Z, Demir MF, Akcay F, Seyrek M, Haksever N, Piskin D, Cimaz R, Rieder MJ, Demirkaya E. Yilmaz MI, et al. Sci Rep. 2020 Jun 2;10(1):9018. doi: 10.1038/s41598-020-65528-6. Sci Rep. 2020. PMID: 32488098 Free PMC article. Clinical Trial.
ADMA and PTX3 levels were independently related to FMD both before and after AAL, AIC and AOL therapies. Our study shows that serum ADMA, MDA, PTX3 levels are associated with endothelial dysfunction in patients with selected chronic diseases. ...
ADMA and PTX3 levels were independently related to FMD both before and after AAL, AIC and AOL therapies. Our study shows that serum A …
Pentraxins: CRP and PTX3 and cardiovascular disease.
Maekawa Y, Nagai T, Anzai A. Maekawa Y, et al. Inflamm Allergy Drug Targets. 2011 Aug;10(4):229-35. doi: 10.2174/187152811796117744. Inflamm Allergy Drug Targets. 2011. PMID: 21539513 Review.
The pentraxins, C-reactive protein (CRP), serum amyloid P (SAP) and pentraxin3 (PTX3) are useful biomarkers for cardiovascular disease (CVD), particularly ischemic heart disease and heart failure, and are deeply involved in the pathogenesis of CVD linked to inflamma …
The pentraxins, C-reactive protein (CRP), serum amyloid P (SAP) and pentraxin3 (PTX3) are useful biomarkers for cardiovascular …
Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases.
Casula M, Montecucco F, Bonaventura A, Liberale L, Vecchié A, Dallegri F, Carbone F. Casula M, et al. Vascul Pharmacol. 2017 Dec;99:1-12. doi: 10.1016/j.vph.2017.10.003. Epub 2017 Oct 16. Vascul Pharmacol. 2017. PMID: 29051088 Review.
Pentraxin 3 (PTX3) is an acute-phase protein that was recently demonstrated to play pleiotropic activities in cardiovascular (CV) diseases. ...The aim of this review is to provide an overview of biological properties of PTX3 in CV diseases and t …
Pentraxin 3 (PTX3) is an acute-phase protein that was recently demonstrated to play pleiotropic activities in cardiovascular ( …
Pentraxin 3: A promising therapeutic target for cardiovascular diseases.
Ye X, Wang Z, Lei W, Shen M, Tang J, Xu X, Yang Y, Zhang H. Ye X, et al. Ageing Res Rev. 2024 Jan;93:102163. doi: 10.1016/j.arr.2023.102163. Epub 2023 Dec 11. Ageing Res Rev. 2024. PMID: 38092307 Review.
This may help in explaining the varying PTX3 functions and usage, as well as in utilizing target organs to manage diseases. Moreover, elucidating the opposite role of PTX3 in the cardiovascular system will demonstrate the therapeutic and predictive pot …
This may help in explaining the varying PTX3 functions and usage, as well as in utilizing target organs to manage diseases. Mo …
Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases.
Bonacina F, Baragetti A, Catapano AL, Norata GD. Bonacina F, et al. Mediators Inflamm. 2013;2013:725102. doi: 10.1155/2013/725102. Epub 2013 Apr 7. Mediators Inflamm. 2013. PMID: 23690668 Free PMC article. Review.
Pentraxins share a common C-terminal pentraxin domain, which in the case of PTX3 is coupled to an unrelated long N-terminal domain. PTX3 in humans, like CRP, correlates with surrogate markers of atherosclerosis and is independently associated with the risk of develo …
Pentraxins share a common C-terminal pentraxin domain, which in the case of PTX3 is coupled to an unrelated long N-terminal domain. …
Pentraxins and atherosclerosis: the role of PTX3.
Garlanda C, Bottazzi B, Moalli F, Deban L, Molla F, Latini R, Mantovani A. Garlanda C, et al. Curr Pharm Des. 2011;17(1):38-46. doi: 10.2174/138161211795049750. Curr Pharm Des. 2011. PMID: 21226667 Review.
Here we will concisely review the general properties of PTX3 in the context of the pentraxin superfamily and discuss recent data suggesting that PTX3 plays a cardiovascular protective effect. PTX3 may represent a new marker in vascular pathology which …
Here we will concisely review the general properties of PTX3 in the context of the pentraxin superfamily and discuss recent data sugg …
Pentraxin-3 and endothelial dysfunction.
Zlibut A, Bocsan IC, Agoston-Coldea L. Zlibut A, et al. Adv Clin Chem. 2019;91:163-179. doi: 10.1016/bs.acc.2019.03.005. Epub 2019 May 4. Adv Clin Chem. 2019. PMID: 31331488 Review.
Pentraxin 3 (PTX3) is involved in vascular inflammation and endothelial dysfunction through various mechanisms. ...PTX3 modulates inflammatory cells, thus stimulating vascular inflammation. ...
Pentraxin 3 (PTX3) is involved in vascular inflammation and endothelial dysfunction through various mechanisms. ...PTX3 modula …
Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases.
Atzeni F, Turiel M, Hollan I, Meroni P, Sitia S, Tomasoni L, Sarzi-Puttini P. Atzeni F, et al. Autoimmun Rev. 2010 Oct;9(12):845-8. doi: 10.1016/j.autrev.2010.08.001. Epub 2010 Aug 6. Autoimmun Rev. 2010. PMID: 20692380 Review.
Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic inflammation is an important factor in the development of atherosclerotic plaque and endothelial dysfunction. The levels of biomarkers such as s …
Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic infl …
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Xu Z, Gao Z, Fu H, Zeng Y, Jin Y, Xu B, Zhang Y, Pan Z, Chen X, Zhang X, Wang X, Yan H, Yang X, Yang B, He Q, Luo P. Xu Z, et al. Cardiovasc Res. 2023 May 22;119(5):1250-1264. doi: 10.1093/cvr/cvad012. Cardiovasc Res. 2023. PMID: 36651911 Free PMC article.
PTX3 affected calcium homoeostasis in cardiomyocytes, which led to defective contractile properties. EGFR/STAT3 signalling in VECs contributed to the increased expression and release of PTX3. Notably, lapatinib, a dual inhibitor of EGFR/HER2, could rescue the cardia …
PTX3 affected calcium homoeostasis in cardiomyocytes, which led to defective contractile properties. EGFR/STAT3 signalling in VECs co …
493 results